Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 3, 2013, Pages 261-268

  Hong, Bujung ^a   Wiese, Bettina ^a   Bremer, Michael ^b   Heissler, Hans E ^a   Heidenreich, Fedor ^a   Krauss, Joachim K ^a   Nakamura, Makoto ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Hannover Medical School ^*  (Germany)

Author keywords

glioblastoma multiforme; multiple resections; repeated recurrence; survival rate

Indexed keywords

TEMOZOLOMIDE; TENIPOSIDE;

ADULT; AGED; ARTICLE; BRAIN ABSCESS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; KARNOFSKY PERFORMANCE STATUS; MALE; MICROSURGERY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; SUBDURAL HEMATOMA; SURVIVAL RATE; TUMOR RECURRENCE; WOUND HEALING IMPAIRMENT;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878856242     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3182467bb1     Document Type: Article

References (64)

1. Stummer W, Picchlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392-401.
2. Butowski N, Lamborn KR, Berger MS, et al. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol. 2007;85:87-94.
3. Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro-oncol. 2008;10:79-87.
4. Gorlia T, van den Bent MJ, Hegi ME, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2008;9:29-38.
5. Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg. 1986;65:654-658.
6. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21:607-614.
7. Stupp R, Mason WP, van den Bent NJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
8. Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology. 2006;66:587-589.
9. Brandes AA, Tosoni A, Cavallo G, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperative di neuro-oncologia (GICNO). Br J Cancer. 2006;95:1155-1160.
10. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26:5610-5617.
11. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27: 740-745.
12. Glas M, Hundsberger T, Stuplich M, et al. Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma. Oncology. 2009;76:184-189.
13. Wick A, Felsberg J, Steinbach JP, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007;25:3357-3361.
14. Aoki T, Mizutani T, Nojima K, et al. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme. J Neurosurg. 2010;112:50-56.
15. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28:2817-2823.
16. Rethmeier T, Graf E, Piroth T, et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer. 2010;10:30.
17. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-Oncol. 2010;12: 304-316.
18. Perry JR, Bélanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28:2051-2057.
19. Harsh GR, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987;21: 615-621.
20. Kaye AH. Re-operation for recurrent malignant brain tumours: is it worthwhile? Aust N Z J Surg. 1992;62:677-679.
21. Pang BC, Wan WH, Lee CK, et al. The role of surgery in highgrade glioma-is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore. 2007;36:358-363.
22. Landy HJ, Feun L, Schwade JG, et al. Retreatment of intracranial gliomas. South Med J. 1994;87:211-214.
23. Durmaz R, Erken S, Arslantaş A, et al. Management of glioblastoma multiforme: with special reference to recurrence. Clin Neurol Neurosurg. 1997;99:117-123.
24. Barker FG II, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42:709-720.
25. Salvati M, Piccirili M, Caroli E, et al. Treatment of glioblastoma multiforme in the elderly in functionally non-critical areas. Clinical remarks on 22 patients. J Exp Clin Cancer Res. 2003; 22:395-398.
26. Mahajan A, McCutcheon IE, Suki D, et al. Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg. 2005;103:210-217.
27. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130:2596-2606.
28. Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008;69:506-509.
29. Hottinger AF, Yoon H, DeAngelis LM, et al. Neurological outcome of long-term glioblastoma survivors. J Neurooncol. 2009; 95:301-305.
30. Wick W, Steinbach JP, Küker WM, et al. One week on/one week off: a novel active regimen on temozolomide for recurrent glioblastoma. Neurology. 2004;62:2113-2115.
31. Weller M, Mü ller B, Koch R, et al. Neuro-oncology Working Group of the German Cancer Society. Neuro-oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J Clin Oncol. 2003;21:3276-3284.
32. Levin VA, Edwards MS, Wright DC, et al. Modified procarbazine, CCNU, and vincristine (PCV3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep. 1980; 64:237-244.
33. Hou LC, Veeravagu A, Hsu AR, et al. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20:E5.
34. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10:162-170.
35. Toth J, Egervari K, Klekner A, et al. Analysis of EGFR gene amplification, protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma. Pathol Oncol Res. 2009;15: 225-229.
36. Brandes AA, Tosoni A, Franceschi E, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27:1275-1279.
37. Liu W, Fu Y, Xu S, et al. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J Clin Neurosci. 2011;18:119-121.
38. Shepherd SF, Laing RW, Cosgrove VP, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys. 1997;37:393-398.
39. Hudes GR, Corn BW, Werner-Wasik M, et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys. 1999;43:293-298.
40. Cho KH, Hall WA, Gerbi BJ, et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;45:1133-1141.
41. Arcicasa M, Roncadin M, Bidoli E, et al. Reirradiation and lomustine in patients with relapsed high-grade gliomas. Int J Radiat Oncol Biol Phys. 1999;43:789-793.
42. Voynov G, Kaufman S, Hong T, et al. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002;25:606-611.
43. Lederman G, Wronski M, Arbit E, et al. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol. 2000; 23:155-159.
44. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol. 2005; 23:8863-8869.
45. Vordermark D, Kölbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55.
46. Grosu AL, Weber WA, Franz M, et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:511-519.
47. Bartsch R, Weitmann HD, Pennwieser W, et al. Retrospective analysis of re-irradiation in malignant glioma: a single-center experience. Wien Klin Wochenschr. 2005;117:821-826.
48. Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose. Observations from a randomized dose-escalation trial for malignant glioma (Radiation Therapy Oncology Group 83-02). Cancer. 1994;74: 2828-2835.
49. Crossen JR, Garwood D, Glatstein E, et al. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiationinduced encephalopathy. J Clin Oncol. 1994;12:627-642.
50. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapyinduced necrosis of the brain after treatment. Radiology. 2000; 217:377-384.
51. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244.
52. Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003;30:10-14.
53. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62:564-576.
54. Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery. 2008;62:753-760.
55. Ryken TC, Frankel B, Julien T, et al. Surgical management of newly diagnosed glioblastoma in adults: role of cytoreductive surgery. J Neurooncol. 2008;89:271-286.
56. Peca C, Pacelli R, Elefante A, et al. Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? Clin Neurol Neurosurg. 2009;111:331-334.
57. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection and survival. J Neurosurg. 2001;95:190-198.
58. Donahue B, Scott CB, Nelson JS, et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int J Radiat Oncol Biol Phys. 1997;38:911-914.
59. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003; 99:467-473.
60. Kurimoto M, Hayashi N, Kamiyama H, et al. Impact of neuronavigation and image-guided extensive resection for adult patients with supratentorial malignant astrocytomas: a single-institution retrospective study. Minim Invasive Neurosurg. 2004;47:278-283.
61. Berman JI, Berger MS, Chung SW, et al. Accuracy of diffusion tensor magnetic resonance imaging tractography assessed using intraoperative subcortical stimulation mapping and magnetic source imaging. J Neurosurg. 2007;107:488-494.
62. Guggisberg AG, Honma SM, Findlay AM, et al. Mapping functional connectivity in patients with brain lesions. Ann Neurol. 2007;63:193-203.
63. Gasco J, Tummala S, Mahajan NM, et al. Simultaneous use of functional tractography, neuronavigation-integrated subcortical white matter stimulation and intraoperative magnetic resonance imaging in glioma surgery: technical note. Stereotact Funct Neurosurg. 2009;87:395-398.
64. Feigl GC, Ritz R, Moraes M, et al. Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg. 2010;113:352-357.